Commercial Readiness: Two Sides of the Exit Coin
Written by ILIKOS CG
In today’s tighter funding environment, a strong track record alone is no longer enough to secure a premium valuation.
For Life Sciences service providers, investors are looking far beyond historical revenue. They want to understand the quality of that revenue, how predictable it is, how scalable the commercial model is, and whether the business is truly positioned for long-term growth or a successful exit. That is exactly why conversations like this one matter.
In the webinar Commercial Readiness: Two Sides of the Exit Coin, industry leaders from ILIKOS Consulting Group, Bourne Partners, and Zymewire came together to unpack what it really takes to build an acquisition-ready, investor-ready commercial engine in today’s market.
The session featured:
- Elias Sayias, Founder, ILIKOS Consulting Group
- Ryan Silvester, Investment Banker, Bourne Partners
- Ali Babar, Director of Sales, Zymewire
Held on March 4, 2026, at 11:00 AM EST (18:00 EET), the webinar brought together three different but highly connected perspectives – frontline commercial strategy, mid-market investment banking, and data-driven market intelligence – for a discussion focused on how Life Sciences organisations can strengthen their commercial maturity and increase enterprise value.
This was not a theoretical conversation. It was a practical discussion built around a real market shift.
As capital becomes more selective and diligence becomes more intense, businesses can no longer rely on reactive business development, existing relationships, or conference-driven momentum alone. Investors want to see a structured commercial engine. They want evidence of clear market positioning, repeatable growth processes, credible forecasts, and operational discipline. In other words, they want to see a business that is not only functioning but also de-risked and scalable.
That is where this webinar delivered real value.
The conversation explored how Life Sciences service providers can bridge the gap between internal commercial operations and external investment expectations. It addressed the financial benchmarks and operational frameworks that can move a company from being simply active in the market to being viewed as a serious premium acquisition target.
For Elias Sayias, Founder of ILIKOS Consulting Group, this topic reflects the core of the work ILIKOS does every day.
With more than 15 years of experience connecting clinical operations with global commercial strategy, Elias has helped CROs and MedTech organisations generate over $250 million in new revenue through tactical, market-driven go-to-market solutions. In this webinar, he brought a grounded and practical perspective to the discussion, highlighting the importance of moving beyond traditional sales habits and building a sophisticated commercial function that can support both growth and valuation.
Alongside him, Ryan Silvester of Bourne Partners offered the investment banking lens. Representing a firm with a 25-year legacy in healthcare finance, Ryan shared insight into the value drivers that matter most in global M&A and financing advisory across Pharma Services and Healthcare Technology. His perspective helped frame how investors evaluate businesses not just on past performance, but on future confidence.
Ali Babar of Zymewire added the commercial intelligence perspective, drawing on his multidisciplinary background in scientific research and commercial advisory. His contribution reinforced the importance of using data, signal tracking, and a more analytical commercial framework to help organisations identify real opportunities and create scalable growth systems.
Together, the speakers tackled several of the most pressing questions facing Life Sciences organisations today.
Why does commercial maturity matter more than ever? What does an exit-ready commercial engine actually look like? Which KPIs and investor metrics drive premium valuations? And how can a business move from reactive selling to a proactive, credible, and scalable growth model?
Among the key themes discussed in the webinar were:
- The Stakes: Why Commercial Maturity Matters
The session examined why current market conditions are forcing companies to rethink how they define growth. In today’s environment, investors are placing greater emphasis on de-risked revenue, commercial visibility, and TAM credibility. - Building the Exit-Ready Commercial Engine
The speakers explored the pillars of a stronger commercial organization, including tactical business development methodology, more intentional market positioning, and the importance of developing a diverse and winnable project mix. - Securing the Premium: Investor Metrics
A major focus of the discussion was on the commercial and financial KPIs that matter during diligence. From Backlog and Net Revenue Retention to building a credible TAM-SAM-SOM roadmap, the webinar outlined the metrics that can directly influence valuation and investor confidence.
This conversation was especially relevant for small-to-mid-sized CROs, CDMOs, clinical sites, and eClinical platforms looking to professionalise their commercial engine. It was also highly valuable for C-suite executives, VPs, Directors of Business Development, and high-growth commercial leaders who are preparing for an eventual exit, acquisition, or capital raise.
One of the most important messages from the webinar was simple: commercial readiness is no longer optional.
If business development still feels reactive, overly dependent on existing relationships, or disconnected from a clear strategic framework, that creates risk. And in today’s market, risk impacts valuation assessments fast. Businesses that want to command stronger valuations need more than revenue. They need commercial credibility. They need a scalable engine. They need a story that stands up in front of investors, buyers, and diligence teams.
That is why Commercial Readiness: Two Sides of the Exit Coin is such a timely and relevant discussion.
For ILIKOS, participation in this webinar reflects a broader commitment to helping Life Sciences service providers build stronger commercial foundations, sharpen their market positioning, and prepare for growth with purpose. For the audience, it offers a valuable opportunity to hear how investment, commercial strategy, and market intelligence intersect in a way that can directly impact enterprise value.
Whether you are assessing your path toward future investment, looking to strengthen your commercial structure, or simply trying to understand what buyers and investors expect in today’s market, this webinar offers practical insight worth your time.
Watch the full webinar recording below and explore the key strategic takeaways from Elias Sayias, Ryan Silvester, and Ali Babar.
